Harmony Biosciences
HRMY
182 hedge funds and large institutions have $2.21B invested in Harmony Biosciences in 2022 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 76 increasing their positions, 42 reducing their positions, and 10 closing their positions.
350% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 10
81% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 42
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
24% more funds holding
Funds holding: 147 → 182 (+35)
16% more capital invested
Capital invested by funds: $1.9B → $2.21B (+$310M)
2.16% more ownership
Funds ownership: 76.21% → 78.38% (+2.2%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $224K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$28.1M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$22.4M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$16.5M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$12.2M |
| 5 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$12.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
-$48.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$25.2M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$12.8M |
| 4 |
PA
Perceptive Advisors
New York
|
-$10.2M |
| 5 |
NP
Newlight Partners
New York
|
-$10.2M |
HRMY Hedge Fund Activity: Q1 2022 in Review
182 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q1 2022, worth a combined $2.21B — up 16% from $1.9B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new HRMY positions and 10 closed out — a net gain of 35 holders — while 76 added to existing stakes and 42 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $28.1M. The largest seller was venBio Partners, cutting an estimated $48.8M.
- 182 institutional investors held Harmony Biosciences (HRMY) as of Q1 2022, up from 147 in Q4 2021.
- Funds reported $2.21B of Harmony Biosciences stock for Q1 2022, up 16% quarter-over-quarter.
- 45 funds opened new Harmony Biosciences positions in Q1 2022 and 10 closed out, a net change of +35 holders.
- The largest Harmony Biosciences buyer in Q1 2022 was Fidelity Investments, an estimated $28.1M added.
- The largest Harmony Biosciences seller in Q1 2022 was venBio Partners, an estimated $48.8M sold.
Based on aggregated 13F filings for Q1 2022.